The study, led by Mathieu Wimmer, PhD, a post-doctoral researcher in the laboratory of R. Christopher Pierce, PhD, associate professor of Neuroscience in Psychiatry at the Perelman School of Medicine at the University of Pennsylvania, found that sons, but not females, of male rats on cocaine were not only less likely to want the drug, but also resistant to effects of it. This suggests cocaine causes epigenetic changes—that is alterations to DNA that do not involve changing the sequence—in sperm in which reprogrammed information is transmitted down to the next generation of men.
Last year, Dr. Pierce and colleagues found that cocaine abuse in a male rat rendered the next generation of animals resistant to the rewarding properties of the drug—those offspring were less likely to take cocaine. They found changes in the brain-derived neurotrophic factor (BDNF), which is a molecule known to be important for the rewarding efficacy of cocaine, but only by looking at molecular signaling pathways in progeny that had never experienced cocaine.
In the current study, the authors focused on the physiology of neurons before and after taking cocaine in the offspring of cocaine-experienced fathers, and found that they were less sensitive to the drug and less likely to succumb to addictive behaviors.
In short, not only are rat offspring of cocaine-abusing fathers less likely to take the drug on their own volition, they are less likely to become addicted to it if they are administered it.
In male rats whose fathers used cocaine, the neurons in the nucleus accumbens were less sensitive to cocaine. That is, repeated cocaine use in the sons of cocaine-experienced fathers did not cause remodeling of excitatory AMPA receptors, which is thought to be critical for the development of addiction and cocaine craving.
“This adds to the growing body of evidence that cocaine abuse in a father rat can affect how his sons may respond to the drug—and point to potential mechanisms that contribute to this phenomenon,” said Wimmer. “Further research is needed to better understand how these behavior changes are passed down from one animal generation to the next, and eventually if the same holds true for humans.”
Penn Medicine co-authors of the abstract include Pavel Ortinski, Samantha L. White and Heath D. Schmidt, and R. Christopher Pierce
This research was supported with funds from the National Institutes of Health and the National Institute on Drug Abuse.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report‘s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania — recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital — the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.